Medically Underrepresented Populations In National Cancer Institute (NCI) Sponsored Cancer Clinical Trials: Refining the Calculation of Accrual Targets.

e17598 Background: Equitable accrual of underrepresented populations to cancer clinical trials is lacking, resulting in failure to achieve distributive justice in clinical research, and uncertainty in applying outcomes to the underrepresented.. No validated metric exists to accurately identify accrual targets for underrepresented groups. Currently, percentages are derived from the general population to set targets for NCI-sponsored trials, with performance determined from actual accruals and does'nt consider disease specific and demographic variances. We propose a metric to establish targets that more accurately measure performance. Methods: Accrual to US NCI-funded Cooperative Group clinical trials for 2007Q1-2014Q1 (~160,000 cases), SEER risk rates and US census data were used to estimate accrual targets. Each accrual is apportioned with expected values based on patient demographics, disease site and expected accrual by population. Performance estimates were determined by comparing actual accruals to th...